Among the patients not meeting the NCCN criteria, three P/LP variants were identified (6%, 3/50) in moderate-penetrance breast cancer susceptibility genes (CHEK2 and ATM) and Lynch syndrome-associated genes (MSH2) (see details in Supplementary Table S2). This evidence concerns the gene CHEK2 and breast cancer.